Scar channels in cardiac magnetic resonance to predict appropriate therapies in primary prevention

Paula Sánchez-Somonte, MD, *†‡ Levío Quinto, MD, *† Paz Garre, BEng, *† Fatima Zaraket, MD, *† Francisco Alarcón, BEng, *‡‡ Roger Borràs, MSc, *† Gala Caixal, MD, *† Sara Vázquez, MD, *† Susanna Prat, MD, PhD, *† Jose T. Ortiz-Perez, MD, PhD, *† Rosario Jesús Perea, MD, *† Eduar Guasch, MD, PhD, *‡‡ José María Tolosana, MD, PhD, *‡‡ Antonio Berruezo, MD, PhD, *† Elena Arbelo, MD, PhD, *‡‡ Marta Sitges, MD, PhD, *‡‡ Lluís Mont, MD, PhD, *‡‡ Ivo Roca-Luque, MD, PhD *†‡‡

From the *Institut Clinic Cardiovascular, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain, †Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ‡Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, and §Centre de Diagnòstic per la Imatge, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.

BACKGROUND Scar characteristics analyzed by late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) are related with ventricular arrhythmias. Current guidelines are based only on the left ventricular ejection fraction to recommend an implantable cardioverter-defibrillator (ICD) in primary prevention.

OBJECTIVES Our study aims to analyze the role of imaging to stratify arrhythmogenic risk in patients with ICD for primary prevention.

METHODS From 2006 to 2017, we included 200 patients with LGE-CMR before ICD implantation for primary prevention. The scar, border zone, core, and conducting channels (CCs) were automatically measured by a dedicated software.

RESULTS The mean age was 60.9 ± 10.9 years; 81.5% (163) were men; 52% (104) had ischemic cardiomyopathy. The mean left ventricular ejection fraction was 29% ± 10.1%. After a follow-up of 4.6 ± 2 years, 46 patients (22%) reached the primary end point (appropriate therapies). Scar mass (36.2 ± 19 g vs 21.7 ± 10 g; P < .001), core mass (26.4 ± 12.5 g vs 16.0 ± 9.5 g; P < .001), and CC mass (3.0 ± 2.6 g vs 1.6 ± 2.3 g; P < .001) were associated with appropriate therapies. Core mass > 10 g (25.31% vs 5.26%; hazard ratio 4.74; P = .034) and the presence of CCs (34.75% vs 8.93%; hazard ratio 4.07; P = .003) were also strongly associated with the primary end point. However, patients without channels and with scar mass < 10 g had a very low rate of appropriate therapies (2.8%).

CONCLUSION Scar characteristics analyzed by LGE-CMR are strong predictors of appropriate therapies in patients with ICD in primary prevention. The absence of channels and scar mass < 10 g can identify patients at a very low risk of ventricular arrhythmias in this population.

KEYWORDS Ventricular tachycardia; Cardiac magnetic resonance; Scar; Border zone; Conducting channels

Introduction

In the last decades, cardiovascular mortality has decreased in developed countries because of the adoption of preventive measures to reduce the burden of ischemic heart disease and heart failure. Nevertheless, cardiovascular diseases are still the main cause of death in these countries and 25% of them are related with sudden cardiac death (SCD). Currently, clinical practice guidelines for recommending an implantable cardioverter-defibrillator (ICD) for the primary prevention of SCD are based only on the left ventricular ejection fraction (LVEF). The European Society of Cardiology and American College of Cardiology/American Heart Association...
guidelines recommend ICD implantation for the primary prevention of SCD in patients with heart failure and reduced LVEF on the basis of the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) and the Sudden Cardiac Death in Heart Failure Trial.

Although LVEF can identify a subgroup of patients at risk of SCD, appropriate ICD therapy is documented in only one-third of the patients, so its use as the sole criterion for implanting an ICD implies overtreatment of a high number of patients. Thus, tools for improving the prediction of arrhythmic risk are needed.

Currently, it is well known that the presence of scar tissue is a substrate for malignant reentrant arrhythmias and several studies have shown that infarct size assessed by late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) is an independent predictor of arrhythmic events. The aim of our study was to analyze the role of imaging to predict which patients with decreased LVEF are at risk of developing life-threatening arrhythmias and therefore would benefit from ICD implantation.

Methods
Patients
We performed a prospective registry of 224 consecutive patients with ischemic and nonischemic systolic dysfunction (LVEF ≤35%) who underwent LGE-CMR between 2011 and 2017 before ICD implantation for primary prevention. Coronary disease was diagnosed by coronary angiography or computed tomography angiography. Incomplete revascularization was considered when ≥1 vessels with severe lesions were not revascularized percutaneously or surgically or when there was chronic total occlusion. The study was approved by the institutional ethics committee. We analyzed this registry retrospectively.

LGE-CMR acquisition and processing
All CMR studies were performed with a 3T MAGNETOM Trio scanner (Siemens Healthcare, Erlangen, Germany), and the images were processed with ADAS 3D software (ADAS3D Medical S.L., Barcelona, Spain) following a previously described protocol. Briefly, 2 independent investigators analyzed the CMR images and a third observer was available in case of discrepancies. Full left ventricular volume was reconstructed in the axial orientation, and the resulting images were processed with ADAS3D software. After semiautomatically delineating the endocardium and epicardium, 9 concentric layers were created automatically from the endocardium to the epicardium at 10%–90% of the left ventricular wall thickness. A 3-dimensional shell was obtained for each layer. Pixel signal intensity maps were obtained from LGE-CMR images and projected to each of the shells following a trilinear interpolation algorithm and were color coded (core scar in red, border zone [BZ] in light yellow, and healthy tissue in blue). A pixel signal intensity–based algorithm was applied to characterize the hyperenhanced area as scar core or BZ by using 40% ± 5% (healthy tissue) and 60% ± 5% (core scar) of the maximum intensity signal as thresholds. A conducting channel (CC) in LGE-CMR reconstruction was defined as a corridor of the BZ between 2 core areas or between a core area and a valve annulus (Figure 1).

ICD implantation and follow-up
After implantation, 2 detection zones were programmed: ventricular tachycardia (VT) zone from 170 to 220 beats/min and ventricular fibrillation (VF) zone at a detection rate of >220 beats/min (as per protocol for primary prevention in our institution). In all patients, shocks were programmed in the VF zone. The VT zone therapy was

Figure 1  A: LGE-CMR reconstruction of the LV with a posteroseptal scar (core in red, BZ in white, and healthy myocardium in blue). A white line is drawn over the surface, representing a conducting channel. We can see the substrate evolution through different layers, from the endocardium (10%–30%) to the epicardium (70%–90%), with a defined channel in different layers. B: LGE-CMR reconstruction of the LV with an anterior scar. In this case the scar is very homogeneous (mainly composed of core tissue) compared with the scar in panel A and it has no conducting channels. C: LGE-CMR reconstruction of the LV without scar. BZ = border zone; LGE-CMR = late gadolinium enhanced cardiac magnetic resonance; LV = left ventricle.
antiarrhythmia pacing at 91% and 81% of the tachycardia cycle length with 10-ms scan followed by shocks. Device follow-up was performed in our device clinic every 8 months (12 months if patients had remote monitoring). Interrogation was stored in the computer system and was analyzed by the study investigators.

**Definition of end points**
The primary end point was appropriate ICD therapy (antiarrhythmia pacing or shock) for VT or VF. The secondary end point was all-cause mortality.

**Statistical analysis**
Continuous data are reported as mean ± SD, and comparisons between groups were performed using the Student t test or the Mann-Whitney U test, as appropriate. Categorical variables are presented as frequency (percentage) and were compared using the χ² test or Fisher exact method. Receiver operating characteristic curves were calculated to estimate the predictive value of scar variables and to identify cutoff points of interest. For the competing risk analysis, we tabulated the number of patients with each of the 2 outcomes of interest (appropriate ICD therapy and death). Because of the presence of competing risks, to analyze the effect of baseline predictors on the primary end point (appropriate ICD therapy), we used regression modeling of the subdistribution functions to analyze competing risk survival data. Variables selected in the univariable analyses (P < .05) were entered into multivariable subdistribution hazards models to estimate the independent effect of the scar tissue characteristics on event-free survival for both end points. The scar-related variables were included separately in the multivariable analysis because they were strongly related. For all tests, a P value of <.05 was considered statistically significant. Analysis was performed using SPSS 17.0 software (IBM, Armonk, NY) and R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

**Clinical and demographic data**
A total of 226 patients who underwent CMR before ICD implantation for primary prevention were included. Twenty-six patients were excluded because of insufficient CMR image quality, and finally a total of 200 patients were evaluated. Baseline characteristics are listed in Table 1. The mean age of the study population was 60.9 ± 10.9 years; 81.5% (163) were men; and 52% (104) had ischemic cardiomyopathy (ICM). A combined cardiac resynchronization therapy-defibrillator device was implanted in 101 patients (50.5%). Of the 200 patients, 34 did not have LGE in CMR, and of these 34 patients, 30 had nonischemic cardiomyopathy (NICM) and 4 had ICM.

**Predictors of appropriate therapies and SCD**
During a median follow-up of 4.6 ± 2 years, 43 patients (21.5%) reached the primary end point. From those 43 patients who reached the primary end point, 23 patients (53.5%) presented ventricular arrhythmias (VAs) detected in the VT zone, 8 patients (18.6%) in the VF zone, and 12 patients (27.9%) presented VAs in both zones. Only shocks in the VF zone were delivered to 8 patients (18.6%), 16 patients (37.2%) received only antitachycardia pacing in the VT zone, 8 patients (18.6%) in the VF zone, and 12 patients (27.2%) received only antitachycardia pacing plus shocks. The event rate was not different in patients with ICM (26%) from that in patients with NICM (16.7%) (P = .2) and neither in patients with and without resynchronization therapy (P = .3).

Competing risk analysis with cumulative incidence plots of appropriate ICD therapy with death as the competing event was performed. The clinical characteristics and CMR parameters for the prediction of appropriate ICD therapy are listed in Table 2. Neither LVEF and ventricular diameters assessed by echocardiography and neither the presence of comorbidities as hypertension and diabetes were not associated with appropriate therapies.

According to the clinical parameters, patients who received appropriate therapy were younger (hazard ratio [HR] 0.96; 95% confidence interval [CI] 0.93–0.96; P = .003) and less likely to have complete revascularization (HR 0.52; 95% CI 0.29–0.95; P = .03).

According to the CMR parameters, the volumes and all scar parameters were significantly associated with the primary end point: left ventricular end-diastolic volume...
Table 2  Univariable analysis for the primary end point (appropriate ICD therapies) (N = 200)

| Variable                          | No appropriate therapy (n=157) | Appropriate therapy (n=43) | HR     | 95% CI              | P     |
|-----------------------------------|-------------------------------|---------------------------|--------|---------------------|-------|
| Male sex                          | 79.6                          | 88.4                      | 0.62   | 0.24–1.59          | .32   |
| Age (y)                           | 62 ± 10                       | 56.8 ± 12.8               | 0.96   | 0.93–0.96          | .003  |
| Ischemic cardiomyopathy           | 49                            | 62.8                      | 1.49   | 0.81–2.76          | .2    |
| Smoker                            | 16.6                          | 32.6                      | 0.86   | 0.63–1.19          | .37   |
| Hypertension                      | 71.3                          | 69.8                      | 0.87   | 0.45–1.68          | .68   |
| Diabetes                          | 35.7                          | 30.2                      | 0.80   | 0.42–1.53          | .49   |
| Dyslipidemia                      | 60.5                          | 62.8                      | 1.12   | 0.61–2.07          | .72   |
| eGFR mL/(min•1.73 m²)             | 66 ± 20                       | 63.9 ± 19.3               | 1.00   | 0.98–1.01          | .81   |
| CVA                               | 10.2                          | 11.6                      | 1.08   | 0.46–2.54          | .86   |
| NYHA class III–IV                 | 27.2                          | 33.3                      | 1.22   | 0.61–2.43          | .58   |
| Complete revascularization        | 65.6                          | 51.2                      | 0.52   | 0.29–0.95          | .03   |
| β-Blocker therapy                 | 91.1                          | 88.4                      | 0.85   | 0.34–2.13          | .73   |
| Amiodarone therapy                | 10.8                          | 9.3                       | 0.78   | 0.29–2.11          | .62   |

Echocardiographic parameters

| LVEF (%)                          | 29.1 ± 10.3                   | 28.6 ± 9.1                | 1      | 0.97–1.03          | .83   |
| LVEDD (mm)                        | 62.9 ± 12.3                   | 63.8 ± 10.6               | 1.01   | 0.98–1.03          | .54   |
| LVESD (mm)                        | 48.9 ± 12.6                   | 50.9 ± 11.1               | 1.01   | 0.99–1.04          | .31   |

CMR parameters

| LVEF (%)                          | 26.6 ± 10                     | 23.9 ± 8.7                | 0.97   | 0.94–1.01          | .16   |
| LVEDV (mL)                        | 282.2 ± 96.6                  | 352.2 ± 110              | 1      | 1–1.01             | .003  |
| LVESV (mL)                        | 211.8 ± 92.8                  | 252 ± 107.3              | 1      | 1–1.01             | .004  |
| Presence of LGE                   | 78.9                          | 97.7                      | 10.4   | 1.34–74.8          | .025  |
| Scar mass (g)                     | 21.7 ± 10                     | 36.2 ± 19                | 1.04   | 1.03–1.05          | <.001 |
| Scar mass > 10 g                  | 77.07                         | 95.3                      | 4.74   | 1.12–12.0          | .034  |
| BZ mass (g)                       | 16 ± 9.5                      | 26.4 ± 12.5              | 1.06   | 1.04–1.07          | <.001 |
| Core mass (g)                     | 5.5 ± 5.7                     | 9.9 ± 8.6                | 1.06   | 1.04–1.09          | <.001 |
| Presence of channels              | 58.6                          | 88.3                      | 4.07   | 1.59–10.4          | .003  |
| Channel mass (g)                  | 1.6 ± 2.3                     | 3.0 ± 2.6                | 1.15   | 1.06–1.25          | .001  |
| Number of channels                | 1.2 ± 1.4                     | 11.3 ± 2.6               | 1.25   | 1.11–1.14          | <.001 |

Values are presented as mean ± SD or percentage and absolute value unless stated otherwise. Bold values are statistically significant.

BZ = border zone; CVA = cerebrovascular accident; HR = hazard ratio; ICD = implantable cardioverter-defibrillator; LGE = late gadolinium enhancement; other abbreviations as in Table 1.

(352.2 ± 110 mL vs 282.2 ± 96.6 mL; P = .003), left ventricular end-systolic volume (252.0 ± 107.3 mL vs 211.8 ± 92.8 mL; P = .004), scar mass (36.2 ± 19 g vs 21.7 ± 10 g; P < .001), BZ mass (26.4 ± 12.5 g vs 16.0 ± 9.5 g; P < .001), core mass (9.9 ± 8.6 g vs 5.5 ± 5.7 g; P < .001), and CCs (3.0 ± 2.6 g vs 1.6 ± 2.3 g; P < .001), as shown in Figure 2. Likewise having scar mass > 10 g was a strong predictor of appropriate therapies (25.31 vs 5.26%; HR = 4.74; 95% CI 1.12–20; P = .034).

Additionally, at 6-year follow-up, 34.75% of patients with CCs reached the primary end point compared with 8.93% without CC (34.72% vs 8.93%; HR = 4.07; 95% CI 1.59–10.4; P = .003) (Figure 3).

An additional analysis has been performed differentiating patients with VT from patients with only VF during follow-up. In patients with VT, all scar-related parameters were related with the primary end point (scar mass: HR 1.04; 95% CI 1.03–1.1; P < .001; BZ mass: HR 1.06; 95% CI 1.04–1.09; P < .001; core mass: HR 1.08; 95% CI 1.05–1.1; P < .001; channel mass: HR 1.2; 95% CI 1.1–1.3; P < .001; presence of channels: HR 5.69; 95% CI 1.75–18.8; P = .004; and scar mass > 10 g: HR 7.82; 95% CI 1.06–57.8; P = .04). In patients with VF, only scar mass (HR 1.03; 95% CI 1.03–1.04; P < .001), BZ mass (HR 1.04; 95% CI 1.01–1.07; P = .002), and core mass (HR 1.06; 95% CI 1.03–1.1; P < .001) were related with primary end point. However, channel mass (HR 1.12; 95% CI 0.99–1.26; P = .07), the presence of channels (HR 3.02; 95% CI 0.88–10.4; P = .08), and scar mass > 10 g (HR 4.38; 95% CI 0.58–33.2; P = .15) did not reach statistical significance, probably owing to the low number of patients withVF.

Multivariable Cox regression analysis was performed using the covariables age, complete revascularization, left ventricular end-diastolic volume, BZ mass, and the presence of CCs. All of them were independent predictors of the primary end point (Table 3). In addition, 4 different multivariable analysis models including MADIT risk score10 and different CMR scar parameters were used. In all models, scar parameters were independent predictors of the primary end point.

Finally, following a previous study in patients of our group who underwent cardiac resynchronization therapy (CRT),11 we developed an algorithm on the basis of the amount of scar tissue and the presence or absence of CCs to identify patients predicted to receive appropriate therapies. As we can see in Figure 4, those patients with scar mass < 10 g and without CCs had very low risk of having VA during follow-up with respect to those with scar mass > 10 g and...
CCs (HR 9.31; 95% CI 1.25–69.3; \( P = .029 \)). Moreover, from those 36 patients with scar mass < 10 g and without CCs, only 1 reached the primary end point (negative predictive value 97.2%). In contrast, from those 164 patients who had scar mass > 10 g and/or CCs, 42 patients reached the primary end point (positive predictive value 25.6%).

Predictors of all-cause mortality

Among patients in this cohort, 30 patients (15%) died. Non-cardiovascular death was reported in 10 patients (5%), and cardiovascular death was reported in 20 (10%) (heart failure, recurrent myocardial infarction, or arrhythmic storm).

In the univariable Cox regression analysis (Table 4), advanced age (HR 1.06; 95% CI 1.01–1.19; \( P = .009 \)), lower estimated glomerular filtration rate (eGFR) (HR 0.97; 95% CI 0.95–0.99; \( P = .001 \)), diabetes (HR 3.1; 95% CI 1.44–6.7; \( P = .004 \)), prior cerebrovascular accident (CVA) (HR 2.95; 95% CI 1.25–6.98; \( P = .03 \)), and higher New York Heart Association (NYHA) class (HR 2.96; 95% CI 1.32–6.66; \( P = .008 \)) were associated with all-cause mortality. None of the echocardiographic parameters except LVESD (54.53 ± 11.07 mm vs 48.46 ± 12.31 mm; \( P = .01 \)) were associated with the secondary end point. The presence or absence of LGE was not associated with all-cause mortality, nor were any of the scar parameters except the presence of CCs (HR 2.88; 95% CI 1.00–8.35; \( P = .04 \)). Nevertheless, when multivariable Cox regression analysis was performed using the covariables age, diabetes, eGFR, NYHA class, prior CVA, LVESD measured by echocardiography, and the presence of CCs, only the clinical parameters eGFR, NYHA class III–IV, and prior CVA were associated with all-cause mortality (Table 3).

Discussion

Main findings

The presence of LGE and CCs, scar mass, BZ mass, and CCs mass were strong predictors of appropriate ICD therapies in patients with ICM and NICM who received an ICD for primary prevention. Even more important from our point of view, patients without CCs and with scar mass < 10 g were at very low risk of having appropriate therapies, with a high negative predictive value.
Table 3 Multivariable competing risk regression analysis for the primary and secondary end points and for the association between the MADIT risk score and the CMR parameters and the study end point of ICD therapies

| Variable                        | HR (95% CI)     | P     |
|---------------------------------|-----------------|-------|
| **Multivariable competing risk regression analysis for the primary and secondary end points** |                |       |
| **Appropriate ICD therapies**   |                 |       |
| Age                             | 0.95 (0.92–0.98) | <.001 |
| Complete revascularization      | 0.53 (0.30–0.97) | <.001 |
| LVEDV                           | 1.003 (1.00–1.01) | <.001 |
| BZ mass                         | 1.045 (1.03–1.07) | <.001 |
| Presence of channels            | 2.849 (1.06–7.70) | .039  |
| **Mortality**                   |                 |       |
| Age                             | 1.00 (0.94–1.06) | .99   |
| Diabetes                        | 2.71 (1.08–6.8)  | .16   |
| eGFR (mL/min)                   | 0.97 (0.95–0.99) | .005  |
| CVA                             | 3.03 (1.04–8.83) | .04   |
| NYHA class III–IV               | 2.19 (1.13–4.25) | .02   |
| Presence of channels            | 2.16 (0.73–6.40) | .16   |
| **Multivariable analysis for the association between MADIT risk score and CMR parameters to predict appropriate ICD therapies** |                |       |
| Model 1 – MADIT score           | 1.10 (0.96–1.25) | .17   |
| Scar mass                       | 1.03 (1.02–1.05) | <.001 |
| Model 2 – MADIT score           | 1.11 (0.98–1.27) | .11   |
| Border zone mass                | 1.05 (1.03–1.07) | <.001 |
| Model 3 – MADIT score           | 1.12 (0.98–1.27) | .09   |
| Core mass                       | 1.06 (1.03–1.08) | <.001 |
| Model 4 – MADIT score           | 1.18 (1.03–1.34) | .01   |
| Channel mass                    | 1.15 (1.05–1.25) | <.001 |

Bold values are statistically significant.

MADIT = Multicenter Automatic Defibrillator Implantation Trial; other abbreviations as in Tables 1 and 2.

**Scar and VA**

There is a general consensus that current LVEF criteria for identifying patients at high risk of SCD is far from ideal. Given the well-established relation between fibrosis and VA, there is an increasing interest in analyzing the role of CMR in stratifying the risk and in deciding the need for an ICD. Nevertheless, we are still far from the end of the road, and further effort to better stratify the risk of SCD is needed.

In our population, the majority of patients had LGE in CMR images (83%), but, despite this high prevalence of LGE, only 21.55% of them received therapies in follow-up. Therefore, the presence or absence of LGE in CMR alone is probably not sufficient and a better characterization of the scar could improve risk stratification.

In a previous study in patients who underwent CRT, it was already demonstrated that both fibrosis and the BZ mass and CC mass were related to arrhythmic events. However, many patients in that study were carrying CRT pacemakers without defibrillator capacity, so some VAs could have not been detected.

Our study confirms those results in patients with and without CRT and, in addition to the amount of scar tissue, is, to our knowledge, the first to analyze the relation between CCs and arrhythmic events in a population with ICD. Actually, the CCs of BZ tissue are the main substrate for reentrant VTs, and CMR has been shown to be able to detect these CCs. If confirmed by other studies, the presence of CCs, in addition to the presence of LGE itself, would be helpful for evaluating the risk of SCD in patients with decreased LVEF.

In our population, as shown in Figure 4, the risk of arrhythmic events at 6-year follow-up in patients with a small scar (<10 g) and without CCs was very low as compared with the risk in patients with scar mass > 10 g and CCs (2.8% vs 31.2%).

Furthermore, the negative predictive value for patients with no CCs and scar mass < 10 g (who represent the 18% of our cohort) was very high (97.2%). If results are confirmed with larger trials, the benefit of ICD implantation for primary prevention in this group of patients should be discussed.

Among the clinical factors analyzed, incomplete revascularization was shown to be a predictor of the primary end point in addition to scar parameters. Incomplete revascularization (untreated severe lesions or chronic total occlusion) has been related with VAs and with appropriate ICD therapy in primary prevention. Although the mechanism is not clear, incomplete revascularization could be linked to ischemia, which could potentially act as a trigger of VA. Younger age as a predictor for ICD therapy, already suggested by other studies, could be the result of competing events. In addition, a multivariable analysis was performed to check the value of CMR against MADIT risk score, and in all models, scar-related CMR parameters were independent predictors of appropriate therapies.

Finally, in our population, ICM was not a predictor of appropriate therapy compared with those having NICM. However, the study probably lacked sufficient power to analyze the differences between patients with ICM and those with NICM. Indeed, from our cohort, only 34 patients (16.5%) did not have LGE in CMR (30 patients with NICM and 4 with ICM). Therefore, this supports the
Scar parameters and mortality

The scar parameters were not related to mortality in our study, which was not designed to detect a beneficial effect on the survival of patients with NICM and depressed LVEF, as everybody received an ICD. In this sense, it can be hypothesized that the ICD prevented an important number of deaths—the arrhythmia-related death that is the main cause of death related with the scar parameters. As the population was young (61 years), it can be assumed that the risk of non-arrhythmic death in this group is lower than in older populations. This could explain, at least partially, why the amount of arrhythmic death in this group is lower than in older populations.

In the multivariable Cox regression analysis, only having a lower eGFR, prior CVA, and NYHA class III–IV were predictors of mortality. LVEF also tended to be worse in those patients who died, but this association did not reach statistical significance. Because the inclusion criterion was LVEF < 35%, the study could also be insufficiently powered to find significant differences in LVEF between groups.

The survival benefit of primary prevention ICD implantation is better established in patients with ICM. However, there are controversies regarding this benefit in patients with NICM. In the DANISH-MRI trial,19 fibrosis was shown to be an independent predictor of all-cause mortality and arrhythmic events. Nevertheless, no benefit of ICD was observed in relation to the presence or absence of fibrosis. In this setting, an observational study conducted by Gutman et al19 demonstrated a survival benefit of ICD in primary prevention.

To conclude, we strongly believe in the utility of scar characterization with CMR for the risk stratification of VA and SCD in both ICM and NICM, with a relevant role of CC. A small scar mass (<10 g) and the absence of CCs, if validated by other studies, could identify patients without clear benefit of ICD in primary prevention.

Limitations

The study was performed in a cohort from a single center, so it could be susceptible to selection bias. Other limitation of this study is the low incidence of the primary and secondary end points (although they are similar to those reported in

---

**Table 4** Univariable analysis for the secondary end point (mortality) (N = 200)

| Variable                  | Alive | All-cause mortality | HR   | 95% CI          | P    |
|---------------------------|-------|---------------------|------|-----------------|------|
| Male sex                  | 80.6  | 86.7                | 0.78 | 0.27–2.25       | .63  |
| Age (y)                   | 59.8 ± 10.6 | 66.4 ± 11.1 | 1.06 | 1.01–1.19       | .009 |
| Ischemic cardiomyopathy   | 51.2  | 56.7                | 0.91 | 0.43–1.91       | .80  |
| Smoker                    | 20.6  | 16.7                | 0.83 | 0.29–2.4        | .93  |
| Hypertension              | 69.4  | 80                  | 1.94 | 0.77–4.87       | .13  |
| Diabetes                  | 31.3  | 53.3                | 3.1  | 1.44–6.7        | .004 |
| Dyslipidemia              | 58.8  | 73.3                | 1.78 | 0.79–4.03       | .15  |
| eGFR (mL/min)             | 68.15 ± 19.1 | 50.3 ± 16.9 | 0.97 | 0.95–0.99       | .001 |
| CVA                       | 8.2   | 23.3                | 2.95 | 1.25–6.98       | .026 |
| NYHA class III–IV         | 24.1  | 56                  | 2.96 | 1.32–6.66       | .008 |
| Complete revascularization| 65.9  | 43.3                | 0.47 | 0.22–1.01       | .055 |
| β-Blocker therapy         | 92.4  | 80                  | 0.6  | 0.23–1.55       | .314 |
| Amiodarone therapy        | 10.6  | 10                  | 0.85 | 0.26–2.84       | .792 |

**Echocardiographic parameters**

| LVEF (%)                  | 29.4 ± 10.6 | 26.8 ± 6.1 | 0.96 | 0.91–1.01       | .071 |
| LVEDD (mm)                | 62.4 ± 12.2 | 66.9 ± 9.5 | 1.03 | 0.99–1.08       | .067 |
| LVESD (mm)                | 48.4 ± 12.3 | 54.5 ± 11.1 | 1.04 | 1.01–1.08       | .01  |

**CMR parameters**

| LVEF (%)                  | 26.5 ± 10   | 23.3 ± 7.5  | 0.97 | 0.92–1.01       | .135 |
| LVEDV (mL)                | 287.8 ± 97.4 | 311 ± 118.6 | 1.00 | 1.01–10.01      | .197 |
| LVESV (mL)                | 217 ± 97.3  | 239 ± 106.8 | 1    | 1.01–1.01       | .217 |
| Presence of LGE           | 82.4         | 86.6       | 1.22 | 0.42–3.51       | .71  |
| Scar mass (g)             | 24.1 ± 16.1  | 29 ± 16.3  | 1.01 | 0.99–1.04       | .2   |
| BZ mass (g)               | 17.7 ± 10.9  | 21.3 ± 11.6 | 1.02 | 0.99–1.05       | .2   |
| Core mass (g)             | 6.4 ± 6.7   | 7.7 ± 5.9  | 1.03 | 0.98–1.08       | .34  |
| Presence of channels      | 61.2         | 86.7       | 2.88 | 1.08–3.4        | .04  |
| Channel mass (g)          | 1.9 ± 2.5   | 2.3 ± 2.5  | 1.04 | 0.9–1.2         | .59  |
| Number of channels        | 1.39 ± 1.5  | 2.3 ± 2.5  | 1.04 | 0.9–1.2         | .76  |

Values are presented as mean ± SD or percentage and absolute value unless stated otherwise. Bold values are statistically significant.

CI = confidence interval; LGE = late gadolinium enhancement; other abbreviations as in Tables 1 and 2.
previous studies). Furthermore, the sample size was not sufficient for performing more detailed subgroup analyses, for example, according to the type of arrhythmic event. In this sense, very few women were enrolled (only 18.5%); therefore, these results could not be applicable to women. Finally, patients with moderate to severe renal failure were not included in the study as CMR was contraindicated.

Finally, another important limitation is that as in previous ICD trials, shocks were considered a surrogate for SCD; nevertheless, it is not clear that the number of shocks is equivalent to the mortality.

**Conclusion**

Scar mass, BZ mass, and CCs mass are predictors of appropriate therapy in patients eligible to receive an ICD for primary prevention. A combined algorithm with scar mass (with 10 g as a cutoff) and the presence or absence of CCs could improve the risk stratification of SCD with a very high negative predictive value. Scar assessment and scar characterization are likely superior to LVEF for the risk stratification of SCD, but to support this recommendation, further research is needed.

**References**

1. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. ESC Scientific Document Group, 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793–2867.

2. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in Circulation 2018;138:e149–e420]. Circulation 2018;138:e272–e391.

3. Moss AJ, Cannom DS, Daubert JP, et al. Multicenter Automatic Defibrillator Implantation Trial II (MADIT II): design and clinical protocol. Ann Noninvasive Electrocardiol 2006;11:33–91.

4. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006;114:135–142.

5. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarhythmia by an implanted defibrillator. Circulation 2004;110:3760–3765.

6. Arbustini E, Kramer CM, Narula J. Arrhythmogenic potential of border zone after myocardial infarction: scar is more than just a healed wound. JACC Cardiovasc Imaging 2018;11:573–576.

7. Andreu D, Penela D, Acosta J, et al. Cardiac magnetic resonance-aided scar dechanneling: influence on acute and long-term outcomes. Heart Rhythm 2017;14:1121–1128.

8. Jäuregui B, Soto-Iglesias D, Penela D, et al. Follow-up after myocardial infarction to explore the stability of arrhythmogenic substrate: the Footprint study. JACC Clin Electrophysiol 2020;6:207–218.

9. Roca-Luque I, Van Breukelen A, Alarcón F, et al. Ventricular scar channel entrances identified by new wideband cardiac magnetic resonance sequence to guide ventricular tachycardia ablation in patients with cardiac defibrillators. Europace 2020;22:598–606.

10. Younis A, Goldberg JR, Kuttyfa V, et al. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score [published online ahead of print January 8, 2021]. Eur Heart J. https://doi.org/10.1093/eurheartj/ehaa1057.

11. Acosta J, Fernandez-Armesto J, Borrás R, et al. Scar characterization to predict life-threatening arrhythmic events and sudden cardiac death in patients with cardiac resynchronization therapy: the GAUDI-CRT study. JACC Cardiovasc Imaging 2018;11:561–572.

12. Demirel F, Adiyaman A, Timmer JR, et al. Myocardial scar characteristics based on cardiac magnetic resonance imaging is associated with ventricular tachyarrhythmia in patients with ischemic cardiomyopathy. Int J Cardiol 2014;177:392–399.

13. Disertori M, Rigoni M, Pace N, et al. Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction: a meta-analysis. JACC Cardiovasc Imaging 2016;9:1046–1055.

14. Perez-David E, Arenal A, Rubio-Guirreuet JL, et al. Noninvasive identification of ventricular tachycardia-related conducting channels using contrast-enhanced magnetic resonance imaging in patients with chronic myocardial infarction: comparison of signal intensity scar mapping and endocardial voltage mapping. J Am Coll Cardiol 2011;57:184–194.

15. Nombela-Franco L, Mitrof CD, Fernandez-Lozano I. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study). Circ Arrhythm Electrophysiol 2012;5:147–154.

16. Di Marco A, Anguera I, Teruel L, et al. Chronic total occlusion of an infarct-related artery: a new predictor of ventricular arrhythmias in primary prevention implantable cardioverter defibrillator patients. Europace 2017;19:267–274.

17. Saba S, Adelstein E, Wold N, et al. Influence of patients’ age at implantation on mortality and defibrillator shocks. Europace 2017;19:802–807.

18. Elming MB, Hammer-Hansen S, Vogen I, et al. Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure—DANISH-MRI. Am Heart J 2020;221:165–176.

19. Gutman SJ, Costello BT, Papapostolou S, et al. Reduction in mortality from implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy patients is dependent on the presence of left ventricular scar. Eur Heart J 2019;40:542–550.